http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 20:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Oct+15++Filed+by%3A+Kelly+Thomas+Patrick/27199033.html si-local-file:///var/storage/secattach/20261016/27199033.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Oct+15++Filed+by%3A+Kelly+Thomas+Patrick/27199033.html Fri, 16 Oct 2026 20:22:00 -0400 XENE http://www.streetinsider.com/New+Coverage/Guggenheim+Assumes+Xenon+Pharmaceuticals+%28XENE%29+at+Buy/27148813.html <p>Guggenheim analyst Delma Caiati assumes coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Buy rating and a price target of $73.00.</p> <p>For an analyst ratings summary and ratings history on Xenon Pharmaceuticals <a href="http://www.streetinsider.com/rating_history.php?q=XENE">click here</a>. For more ratings news on Xenon Pharmaceuticals <a href="http://www.streetinsider.com/stock_lookup_news.php?q=XENE&amp;type=analyst">click here</a>.</p> <p>Shares of Xenon Pharmaceuticals closed at $38.02 yesterday.</p> http://www.streetinsider.com/New+Coverage/Guggenheim+Assumes+Xenon+Pharmaceuticals+%28XENE%29+at+Buy/27148813.html Mon, 05 Oct 2026 16:08:15 -0400 XENE http://www.streetinsider.com/Press+Releases/Xenon+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27141958.html <p align="justify">VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering http://www.streetinsider.com/Press+Releases/Xenon+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27141958.html Fri, 02 Oct 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Globe+Newswire/Xenon+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27141958.html <p align="justify">VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering http://www.streetinsider.com/Globe+Newswire/Xenon+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27141958.html Fri, 02 Oct 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Insider+Trades/Xenon+Pharmaceuticals+%28XENE%29+Jumps+6%25+Following+a+35%25+Down+Month+As+Insiders+Report+Buys/27133034.html <p>Xenon Pharmaceuticals (NASDAQ: XENE) Jumps 6% Following a 35% Down Month As Insiders Report Buys.</p><ul><li>CFO buys 15,000 lots at $37.316 = </li><li>President & CEO buys 30,000 lots at $37.37</li><li>XENE up 6% today.</li><li>XENE for September down 35%</li><li>XENE YTD is down 13.25%.</li></ul> http://www.streetinsider.com/Insider+Trades/Xenon+Pharmaceuticals+%28XENE%29+Jumps+6%25+Following+a+35%25+Down+Month+As+Insiders+Report+Buys/27133034.html Thu, 01 Oct 2026 09:38:27 -0400 XENE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Sep+30++Filed+by%3A+Kelly+Thomas+Patrick/27132899.html si-local-file:///var/storage/secattach/20261001/27132899.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Sep+30++Filed+by%3A+Kelly+Thomas+Patrick/27132899.html Thu, 01 Oct 2026 09:20:00 -0400 XENE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Sep+30++Filed+by%3A+MORTIMER+IAN/27132885.html si-local-file:///var/storage/secattach/20261001/27132885.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xenon+Pharmaceuticals+++++For%3A+Sep+30++Filed+by%3A+MORTIMER+IAN/27132885.html Thu, 01 Oct 2026 09:19:00 -0400 XENE http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html <p>Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.</p> <p>Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.</p> <p>Earlier in her career, Aulin held senior roles at KPMG http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html Tue, 29 Sep 2026 03:16:11 -0400 DTC DTCFF XENE http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html <p>Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.</p> <p>Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.</p> <p>Earlier in her career, Aulin held senior roles at KPMG http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html Tue, 29 Sep 2026 03:16:11 -0400 DTC DTCFF XENE http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html <p>Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.</p> <p>Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.</p> <p>Earlier in her career, Aulin held senior roles at KPMG http://www.streetinsider.com/Board+Changes/Defence+Therapeutics+names+ex-Xenon+CFO+Sherry+Aulin+to+its+board/27116187.html Tue, 29 Sep 2026 03:16:11 -0400 DTC DTCFF XENE http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Press+Releases/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html <p>Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc.&#160;(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^&#174; technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.</p><p>Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, http://www.streetinsider.com/Newsfile/Defence+Therapeutics+Appoints+Finance+Executive+Sherry+Aulin+to+Its+Board+of+Directors/27116186.html Tue, 29 Sep 2026 03:15:00 -0400 DTC DTCFF XENE http://www.streetinsider.com/Analyst+PT+Change/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2490+at+Jefferies/27109183.html <p>Jefferies analyst Andrew Tsai lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $90.00 (from $100.00) while maintaining a Buy rating.</p><p>The analyst comments "Despite mgmt's surprise disclosure to voluntarily pause azetukalner's (novel Kv7 pill) Phase III patient enrollment in BPD/MDD depression (X-NOVA2 in MDD is still reading out in Q1:27), our investor discussions are reinforcing our view AZK's $1.5-2B+ peak sales prospects in epilepsy remain intact. The Street is pricing in a worse outcome (biotech degrossing is not helping as well), making us think XENE stock recovers on (+) updates as early as Q4:26."</p> http://www.streetinsider.com/Analyst+PT+Change/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2490+at+Jefferies/27109183.html Mon, 28 Sep 2026 05:08:51 -0400 XENE http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2490+at+Jefferies/27109183.html <p>Jefferies analyst Andrew Tsai lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $90.00 (from $100.00) while maintaining a Buy rating.</p><p>The analyst comments "Despite mgmt's surprise disclosure to voluntarily pause azetukalner's (novel Kv7 pill) Phase III patient enrollment in BPD/MDD depression (X-NOVA2 in MDD is still reading out in Q1:27), our investor discussions are reinforcing our view AZK's $1.5-2B+ peak sales prospects in epilepsy remain intact. The Street is pricing in a worse outcome (biotech degrossing is not helping as well), making us think XENE stock recovers on (+) updates as early as Q4:26."</p> http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2490+at+Jefferies/27109183.html Mon, 28 Sep 2026 05:08:51 -0400 XENE http://www.streetinsider.com/Press+Releases/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26+Epilepsy+Summit/27085300.html <p>VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:</p> <ul type="disc"><li><strong>TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, </strong>Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET</li></ul> <p>Details about the presentation, including webcast information, can be found on the <a href="https://www.globenewswire.com/Tracker?data=xILeCEixXqiUc2qPCexFjSU6ewoRlAEAq9tPt3gqpxk-bUid80F5MXttAxDtyhDSJwM0TCXvxmgVBcFvdcmR-d2wAHKh0Qw6MupYtck_y0s=" rel="nofollow" target="_blank">Investors</a> section of Xenon's website. When available, webcasts are posted for replay following the event. http://www.streetinsider.com/Press+Releases/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26+Epilepsy+Summit/27085300.html Mon, 21 Sep 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Globe+Newswire/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26+Epilepsy+Summit/27085300.html <p>VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:</p> <ul type="disc"><li><strong>TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, </strong>Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET</li></ul> <p>Details about the presentation, including webcast information, can be found on the <a href="https://www.globenewswire.com/Tracker?data=xILeCEixXqiUc2qPCexFjSU6ewoRlAEAq9tPt3gqpxk-bUid80F5MXttAxDtyhDSJwM0TCXvxmgVBcFvdcmR-d2wAHKh0Qw6MupYtck_y0s=" rel="nofollow" target="_blank">Investors</a> section of Xenon's website. When available, webcasts are posted for replay following the event. http://www.streetinsider.com/Globe+Newswire/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26+Epilepsy+Summit/27085300.html Mon, 21 Sep 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Press+Releases/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26amp%3B+Epilepsy+Summit/27085297.html <p>VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:</p> <ul type="disc"><li><strong>TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, </strong>Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET</li></ul> <p>Details about the presentation, including webcast information, can be found on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=xILeCEixXqiUc2qPCexFjSU6ewoRlAEAq9tPt3gqpxk-bUid80F5MXttAxDtyhDSJwM0TCXvxmgVBcFvdcmR-d2wAHKh0Qw6MupYtck_y0s=" rel="nofollow" target="_blank">Investors</a> section of Xenon&apos;s website. When available, webcasts are posted for replay following the http://www.streetinsider.com/Press+Releases/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26amp%3B+Epilepsy+Summit/27085297.html Mon, 21 Sep 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Globe+Newswire/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26amp%3B+Epilepsy+Summit/27085297.html <p>VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:</p> <ul type="disc"><li><strong>TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, </strong>Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET</li></ul> <p>Details about the presentation, including webcast information, can be found on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=xILeCEixXqiUc2qPCexFjSU6ewoRlAEAq9tPt3gqpxk-bUid80F5MXttAxDtyhDSJwM0TCXvxmgVBcFvdcmR-d2wAHKh0Qw6MupYtck_y0s=" rel="nofollow" target="_blank">Investors</a> section of Xenon&apos;s website. When available, webcasts are posted for replay following the http://www.streetinsider.com/Globe+Newswire/Xenon+to+Present+at+TD+Cowen+Novel+Mechanisms+in+Neuropsychiatry+%26amp%3B+Epilepsy+Summit/27085297.html Mon, 21 Sep 2026 16:01:00 -0400 XENE http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+Reiterated+at+Buy+by+Stifel+-+MDDBPD+Study+Enrollment+Paused/27078273.html <p>Stifel analyst Paul Matteis reiterated a Buy rating and $86.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).</p><p>The analyst commented, "XENE's decision to temporarily pause enrollment in their MDD/BPD studies is understandably sending shares lower, and until we get the data (1Q27), the stock will likely trade with minimal option value for neuropsych indications--as it already is in the aftermarket. Even if MDD works there's obviously uncertainty now around the commercial profile for AZK in neuropsych-- even if having a positive MDD study would be of significant value to the epilepsy profile/franchise regardless. But with the stock down 25%, what matters http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+Reiterated+at+Buy+by+Stifel+-+MDDBPD+Study+Enrollment+Paused/27078273.html Fri, 18 Sep 2026 07:52:21 -0400 XENE http://www.streetinsider.com/Analyst+PT+Change/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2460+at+Needham/27078177.html (Updated - September 18, 2026 7:15 AM EDT) <p>Needham analyst Serge Belanger lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $60.00 (from $78.00) while maintaining a Buy rating.</p><p>The analyst commented: "XENE has paused enrollment of ongoing psychiatry ph 3 studies (MDD and BPD) due to a higher observed rates of neuropsychiatric AEs (i.e. confusion, somnolence, ataxia and rare cases of psychosis). XENE plans to modify dosing (titration and/or lower doses) to improve tolerability before resuming enrollment. X-NOVA2, the first ph 3 MDD trial, completed enrollment (80% of target 450 pts) and is expected to readout in 1Q27, at which http://www.streetinsider.com/Analyst+PT+Change/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2460+at+Needham/27078177.html Fri, 18 Sep 2026 07:15:46 -0400 XENE http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2460+at+Needham/27078177.html (Updated - September 18, 2026 7:15 AM EDT) <p>Needham analyst Serge Belanger lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $60.00 (from $78.00) while maintaining a Buy rating.</p><p>The analyst commented: "XENE has paused enrollment of ongoing psychiatry ph 3 studies (MDD and BPD) due to a higher observed rates of neuropsychiatric AEs (i.e. confusion, somnolence, ataxia and rare cases of psychosis). XENE plans to modify dosing (titration and/or lower doses) to improve tolerability before resuming enrollment. X-NOVA2, the first ph 3 MDD trial, completed enrollment (80% of target 450 pts) and is expected to readout in 1Q27, at which http://www.streetinsider.com/Analyst+Comments/Xenon+Pharmaceuticals+%28XENE%29+PT+Lowered+to+%2460+at+Needham/27078177.html Fri, 18 Sep 2026 07:15:46 -0400 XENE